Inceptor Bio raises $37 million in Series A Financing


inceptor bio
Inceptor Bio

Inceptor BioBiotechnology company, based in Morrisville (NC), that focuses on cell therapies, has raised $37M through Series A funding.

Kineticos Ventures was the leader of the round.

The company plans to use the funds for its CART lead program to a phase I clinical trial as well as to develop its CARM and CARNK platforms. Additionally, proceeds will support completion of Inceptor Bio’s Advanced Manufacturing Platform (AMP+) facility, a 29,000 square foot, cell and gene therapy GMP manufacturing site located in Gainesville, Florida.

Inceptor Bio, led by Shailesh Mingi, CEO and President and Chief Operation Officer Mike Nicholson Ph.D., is a biotechnology firm that creates multiple next-generation cells and gene therapy platforms. This will allow for treatment of under-served and hard-to-treat types of cancers. Inceptor Bio partners with industry leaders, universities, medical centers and other institutions to advance cell and gene therapy programs beyond discovery phase technologies into Phase I or II clinical assets.

CAR–T, CAR–M, and CAR–NK platforms form the core of a diverse portfolio of cell therapies that focuses on novel mechanisms to enhance cell performance within the tumor microenvironment. A co-stimulatory domain (M83), a proprietary manufacturing process for TMax, and the K62 platform which increase macrophage phagocytic capability and support a M1 anti–tumor phenotype are just a few of the new technologies.

Get latest news from African Startup ecosystem

Latest stories

You might also like...